GlaxoSmithKline Pharmaceuticals Limited share price
NSE: GLAXO · ISIN INE159A01016
Key numbers
- Market cap
- ₹ 47,700 Cr
- Current price
- ₹ 2,815.70
- 52-week high / low
- ₹ 3,121 / 2,088
- Stock P/E
- 44.6
- Book value
- ₹ 133.8
- Dividend yield
- 2.02%
- ROCE
- 66.1%
- ROE
- 49.1%
- Debt to equity
- 0.01
- Sales growth (3 yrs)
- 5.7%
- Profit growth (3 yrs)
- 19.3%
- 1-year return
- 2.5%
About GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers adult and pediatric vaccines, such as Shingrix, Havrix, Fluarix Tetra, Varilrix, Infanrix Hexa, Boostrix, Synflorix, Menveo, and Priorix. It also provides respiratory specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; Trelegy Ellipta for the treatment of chronic obstructive pulmonary disease; and Seretide. In addition, the company offers general medicines, including Augmentin, an oral antibiotic for respiratory tract infections, surgical prophylaxis, dental infections, and skin infections; Ceftum, an anti-infective medicine; Calpol and Calpol T for pain management; Eltroxin for the treatment of hypothyroidism; Neosporin, Betnovate, T-bact, Physiogel, Tenovate, and Flutivate for dermatology indications; and CobadexCZS and CCM, which are mineral, vitamins, and nutrition products. Further, it provides oncology medicines, including Jemperli and Zejula. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its…
Quarterly results
Consolidated figures in ₹ crores
| Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 974 | 805 | 1,041 | 995 | 938 |
| Operating profit | 333 | 251 | 371 | 351 | 296 |
| Net profit | 263 | 205 | 296 | 278 | 237 |
| EPS (₹) | 15.52 | 12.10 | 17.45 | 16.40 | 14.00 |
Concall summary (2026-08-06)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- Thanking you, Yours faithfully For GlaxoSmithKline Pharmaceuticals Limited Ajay Nadkarni Vice President - Administration, Real Estate & Company Secretary L24239MH1924PLC001151 “GlaxoSmithKline Pharmaceuticals Limited Q1 FY 2027 Earnings Call” August 03, 2026 MR.
- So our overall sales growth, as Bhushan mentioned, reflects continued strong execution on all elements of our strategy driving the expected portfolio transformation.
Growth & demand
- So externally, the first quarter for the industry grew at roughly about 13.5%, and after a long time, we've seen this kind of a sustained double-digit growth.
- After a long time, the pharma industry in India has seen almost a 2% volume growth as per the first quarter.
Margins & costs
- EBITDA growth was running slightly ahead of sales, so two percentage points ahead of sales and it grew 17%.
- EBITDA margins also improved by 50 bps versus the last year.
Capex & expansion
- Our profit after tax for the first quarter was at INR253 crores growing 24% with good m argin expansion, 200 basis points taking our PAT margins to 27.6%.
- So the simple answer is there is a concentration, very conscious and deliberate concentration of investment in this quarter.
Balance sheet & cash
- Important to call out, there is a one-off item which is in the here in the standalone, we had a dividend payout from our 100% subsidiary, Biddle Sawyer, which improved to the parent, which improved our PAT growth and that's driving the growth to 24%.
Peers in Drug Manufacturers - General
Data for information only, not investment advice. Prices end of day.